IL283755B1 - n-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing them - Google Patents
n-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing themInfo
- Publication number
- IL283755B1 IL283755B1 IL283755A IL28375521A IL283755B1 IL 283755 B1 IL283755 B1 IL 283755B1 IL 283755 A IL283755 A IL 283755A IL 28375521 A IL28375521 A IL 28375521A IL 283755 B1 IL283755 B1 IL 283755B1
- Authority
- IL
- Israel
- Prior art keywords
- dimethylamino
- naphthalene
- phenyl
- substituted
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776837P | 2018-12-07 | 2018-12-07 | |
| PCT/US2019/064960 WO2020118194A1 (en) | 2018-12-07 | 2019-12-06 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL283755A IL283755A (en) | 2021-07-29 |
| IL283755B1 true IL283755B1 (en) | 2025-12-01 |
Family
ID=70974384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL283755A IL283755B1 (en) | 2018-12-07 | 2021-06-06 | n-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing them |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11078171B2 (enExample) |
| EP (2) | EP3890733B1 (enExample) |
| JP (2) | JP7594787B2 (enExample) |
| CN (1) | CN113395963B (enExample) |
| AU (3) | AU2019392904B9 (enExample) |
| CA (1) | CA3122371A1 (enExample) |
| ES (1) | ES3025468T3 (enExample) |
| IL (1) | IL283755B1 (enExample) |
| MX (2) | MX2021006731A (enExample) |
| WO (1) | WO2020118194A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017281222B2 (en) | 2016-06-23 | 2022-06-16 | The Usa As Represented By The Department Of Veterans Affairs; Dept. Of Veterans Affairs Office Of General Counsel - Pag Iv (024) | Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
| WO2020118194A1 (en) * | 2018-12-07 | 2020-06-11 | University Of Maryland, Baltimore | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS |
| AU2020404305A1 (en) | 2019-12-19 | 2022-08-04 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
| CN116406355A (zh) | 2020-05-18 | 2023-07-07 | Gen1E生命科学公司 | P38α促分裂原活化蛋白激酶抑制剂 |
| US11390581B2 (en) * | 2020-10-29 | 2022-07-19 | Gen1E Lifesciences Inc. | Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate |
| CA3206499A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| CN117120422A (zh) * | 2021-03-23 | 2023-11-24 | Gen1E生命科学公司 | 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂 |
| UY39681A (es) | 2021-03-26 | 2022-10-31 | Novartis Ag | Derivados de ciclobutilo 1,3–sustituidos y sus usos |
| EP4448492A1 (en) | 2021-12-17 | 2024-10-23 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| US20240247001A1 (en) | 2022-12-16 | 2024-07-25 | Astrazeneca Ab | 2,6,9-trisubstituted purines |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
| CN116621794B (zh) * | 2023-05-22 | 2025-03-11 | 上海大学 | 一种5-苄基-2-氨基-1,3-噻唑类衍生物及其合成方法与应用 |
| US12116353B1 (en) * | 2024-04-25 | 2024-10-15 | Genie Lifesciences Inc. | Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR96352E (fr) | 1967-12-29 | 1972-06-16 | Science Union & Cie | Nouveaux dérives du spiro (4,5) decane et leur procédé de préparation. |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| DE19801646A1 (de) | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte alpha,beta-annellierte Butyrolactone |
| JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
| PL350998A1 (en) | 1999-03-24 | 2003-02-24 | Anormed Inc | Chemokine recpetor binding heterocyclic compounds |
| PL224879B1 (pl) * | 2002-09-04 | 2017-02-28 | Pharmacopeia Drug Discovery Inc | Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| MXPA05008288A (es) | 2003-02-13 | 2006-03-21 | Sanofi Aventis Deutschland | Derivados de hexahidropirazino[1,2-a] pirimidin-4,7-diona sustituidos en el nitrogeno, metodo para su produccion y uso como medicamentos. |
| US7297817B2 (en) | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| US20070208015A1 (en) * | 2004-04-13 | 2007-09-06 | Astex Therapeutics, Ltd. | 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators |
| WO2006010082A1 (en) * | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| EP1868616A2 (en) | 2005-03-29 | 2007-12-26 | The University of Maryland, Baltimore | Inhibitors for extracellular signal-regulated kinase docking domains and uses therefor |
| WO2008094319A2 (en) * | 2007-02-01 | 2008-08-07 | The Board Of Regents Of The University Of Texas Sytem | Methods and compositions of trail-death receptor agonists/activators |
| TW200904421A (en) | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| US8778953B2 (en) * | 2008-02-29 | 2014-07-15 | Chroma Therapeutics Ltd. | Inhibitors of P38 map kinase |
| US20120172375A1 (en) | 2008-11-07 | 2012-07-05 | Bruce Trapp | Compounds and methods of promoting oligodendrocyte precursor differentiation |
| WO2010082912A1 (en) | 2009-01-15 | 2010-07-22 | Avalon Pharmaceuticals | Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents |
| WO2010094977A1 (en) | 2009-02-23 | 2010-08-26 | Arrow Therapeutics Limited | Novel biphenyl compounds useful for the treatment of hepatitis c |
| PH12017501176B1 (en) * | 2011-05-03 | 2023-03-08 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| US20150357549A1 (en) | 2013-01-15 | 2015-12-10 | Alex Karl MÜLLER | Rapid Solid-State Reaction of Oxides with Ultraviolet Radiation |
| EA030483B1 (ru) | 2013-04-02 | 2018-08-31 | Респайверт Лимитед | Производные мочевины, полезные в качестве ингибиторов киназы |
| US9025712B2 (en) | 2013-07-30 | 2015-05-05 | Pixart Imaging Inc. | Sensor, clock frequency adjusting system and method thereof |
| CA2931431A1 (en) * | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| PT3357919T (pt) | 2014-02-14 | 2020-02-20 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos antiinflamatórios |
| CN113616656B (zh) * | 2014-03-19 | 2023-02-17 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| GB201417168D0 (en) | 2014-09-29 | 2014-11-12 | Univ Hertfordshire Higher Education Corp | Compounds |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| US10865181B2 (en) | 2014-11-05 | 2020-12-15 | University Of Kansas | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) |
| EP3319938B1 (en) * | 2015-07-10 | 2022-04-06 | University of Maryland, Baltimore | Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof |
| AU2017281222B2 (en) | 2016-06-23 | 2022-06-16 | The Usa As Represented By The Department Of Veterans Affairs; Dept. Of Veterans Affairs Office Of General Counsel - Pag Iv (024) | Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof |
| WO2018085348A1 (en) * | 2016-11-03 | 2018-05-11 | Actavalon, Inc. | Substituted quinolines and methods for treating cancer |
| TW201829381A (zh) | 2016-12-22 | 2018-08-16 | 美商拜奧馬林製藥公司 | 組蛋白脫乙醯基酶抑制劑 |
| EP3720436A4 (en) | 2017-12-06 | 2021-06-02 | Lin Bioscience, Pty Ltd. | TUBULIN INHIBITORS |
| WO2020118194A1 (en) * | 2018-12-07 | 2020-06-11 | University Of Maryland, Baltimore | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| CN116406355A (zh) | 2020-05-18 | 2023-07-07 | Gen1E生命科学公司 | P38α促分裂原活化蛋白激酶抑制剂 |
| CN117120422A (zh) | 2021-03-23 | 2023-11-24 | Gen1E生命科学公司 | 取代的萘基P38α丝裂原活化的蛋白激酶抑制剂 |
-
2019
- 2019-12-06 WO PCT/US2019/064960 patent/WO2020118194A1/en not_active Ceased
- 2019-12-06 EP EP19893204.8A patent/EP3890733B1/en active Active
- 2019-12-06 JP JP2021532311A patent/JP7594787B2/ja active Active
- 2019-12-06 CA CA3122371A patent/CA3122371A1/en active Pending
- 2019-12-06 AU AU2019392904A patent/AU2019392904B9/en active Active
- 2019-12-06 ES ES19893204T patent/ES3025468T3/es active Active
- 2019-12-06 CN CN201980091398.5A patent/CN113395963B/zh active Active
- 2019-12-06 EP EP25161840.1A patent/EP4606792A1/en active Pending
- 2019-12-06 MX MX2021006731A patent/MX2021006731A/es unknown
-
2020
- 2020-05-11 US US16/872,114 patent/US11078171B2/en active Active
-
2021
- 2021-06-06 IL IL283755A patent/IL283755B1/en unknown
- 2021-06-07 MX MX2024004162A patent/MX2024004162A/es unknown
- 2021-06-16 US US17/349,468 patent/US11718595B2/en active Active
-
2022
- 2022-11-04 AU AU2022263608A patent/AU2022263608B2/en active Active
-
2023
- 2023-04-26 JP JP2023072147A patent/JP2023106403A/ja active Pending
- 2023-06-07 US US18/206,925 patent/US12202810B2/en active Active
-
2024
- 2024-05-22 AU AU2024203398A patent/AU2024203398A1/en active Pending
- 2024-12-05 US US18/970,196 patent/US20250100985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3122371A1 (en) | 2020-06-11 |
| JP2023106403A (ja) | 2023-08-01 |
| AU2019392904B2 (en) | 2022-08-25 |
| JP7594787B2 (ja) | 2024-12-05 |
| IL283755A (en) | 2021-07-29 |
| CN113395963A (zh) | 2021-09-14 |
| AU2024203398A1 (en) | 2024-06-06 |
| JP2022511555A (ja) | 2022-01-31 |
| US11078171B2 (en) | 2021-08-03 |
| AU2022263608B2 (en) | 2024-02-29 |
| US20230312498A1 (en) | 2023-10-05 |
| MX2024004162A (es) | 2024-04-23 |
| US20250100985A1 (en) | 2025-03-27 |
| WO2020118194A1 (en) | 2020-06-11 |
| AU2019392904A2 (en) | 2021-08-26 |
| AU2022263608A1 (en) | 2022-12-15 |
| EP4606792A1 (en) | 2025-08-27 |
| EP3890733C0 (en) | 2025-04-16 |
| CN113395963B (zh) | 2024-06-25 |
| EP3890733A4 (en) | 2022-05-04 |
| EP3890733B1 (en) | 2025-04-16 |
| AU2019392904A1 (en) | 2021-07-15 |
| NZ777458A (en) | 2024-03-22 |
| US11718595B2 (en) | 2023-08-08 |
| US20200331874A1 (en) | 2020-10-22 |
| US12202810B2 (en) | 2025-01-21 |
| EP3890733A1 (en) | 2021-10-13 |
| AU2019392904A9 (en) | 2022-08-04 |
| ES3025468T3 (en) | 2025-06-09 |
| AU2019392904B9 (en) | 2022-12-22 |
| MX2021006731A (es) | 2021-09-23 |
| US20210317097A1 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283755B1 (en) | n-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing them | |
| IL323780A (en) | d-Homoperganane compounds and pharmaceutical preparation containing them | |
| IL263082B (en) | New compounds as ototaxin inhibitors and pharmaceutical preparations containing them | |
| IL266611B (en) | Converted n-(3-fluorophenyl)-pyrrolidine substances, and their pharmaceutical compounds | |
| ZA202006647B (en) | Anti-cd24 compositions and uses thereof | |
| HUE052749T2 (hu) | Meloxicamot és rizatriptant tartalmazó gyógyászati készítmények | |
| IL271807A (en) | New compounds and their pharmaceutical preparations for the treatment of leprosy | |
| IL261444A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| IL271759B1 (en) | Pharmaceutical preparations that include anthraxtinib | |
| GB201807053D0 (en) | Pharmaceutical composition | |
| ZA202105752B (en) | Haloallylamine compounds and application thereof | |
| ZA202006541B (en) | Pharmaceutical composition comprising brexpiprazole | |
| IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
| GB201804548D0 (en) | Pharmaceutical compositions | |
| ZA202008034B (en) | Ivosidenib forms and pharmaceutical compositions | |
| GB201808571D0 (en) | Pharmaceutical compositions | |
| GB201808567D0 (en) | Pharmaceutical compositions | |
| IL276783A (en) | The composition and pharmaceutical compound containing it | |
| PL3568203T3 (pl) | Związki i kompozycje | |
| SG11202103374TA (en) | Pharmaceutical composition | |
| IL287316A (en) | compounds and preparations | |
| ZA202003079B (en) | Pharmaceutical compositions comprising safinamide | |
| GB201808668D0 (en) | Compounds and compositions and uses thereof | |
| GB201907230D0 (en) | Compounds and compositions and uses thereof | |
| GB201820689D0 (en) | Pharmaceutical composition |